A Phase II Study of Docetaxel Plus Carboplatin in Chemonaive Hormone-Refractory Prostate Cancer (HRPC) Patients
Status:
Completed
Trial end date:
2010-05-01
Target enrollment:
Participant gender:
Summary
The primary objective is to determine the efficacy of docetaxel plus carboplatin as first
line treatment in patients with hormone refractory prostate cancer.